Table of Contents For Ex. 1020A
`
`Declaration of Scott Bennett
`
`Declaration of Scott Bennett ----------------------------------------------- pages 1 - 3
`
`Attachment 1: Program cover of the Fifteenth Meeting of the European
`Neurological Society (ENS) ------------------------------------------------ page 4
`
`Attachment 2: ENS Meeting Program entry for Item 1 ----------------- page 5
`
`Attachment 3: Cover of the Journal of Neurology, 22, Supplement 2 (June 2005)
`from the University of Maryland ------------------------------------------- page 6
`
`Attachment 4: Item 1 from the Journal of Neurology, 22, Supplement 2 (June
`2005), p. II/148 ---------------------------------------------------------------- page 7
`
`Attachment 5: Index entry for Item 1 from the Journal of Neurology, 22,
`Supplement 2 (June 2005), p. II/164 ---------------------------------------- page 8
`
`Attachment 6: University of Maryland Library catalog record for the Journal of
`Neurology ---------------------------------------------------------------------- page 9
`
`Attachment 7: OCLC WorldCat record for the Journal of Neurology - page 10
`
`Attachment 8: Web of Science entry for Item 1 --------------------------- page 11
`
`Attachment 9: SpringerLink entry for Item 1 download ----------------- page 12
`
`
`
`
`
`Page 1 of 13
`
`

`
`SCOTT BENNETT 
`Managing Partner, Prior Art Documentation Services LLC 
`
` 
`
`29 April 2015 
` 
`DECLARATION 
`
` 
`I, Scott Bennett, am a retired academic librarian working at 711 South Race Street, Urbana, IL, 61801‐
`4132.  I was employed as a librarian as follows: 
`
` 
`
` University Librarian, Yale University, New Haven, CT., 1994‐2001 
` Director, The Milton S. Eisenhower Library, The Johns Hopkins University, Baltimore, MD, 1989‐
`1994 
` Assistant University Librarian for Collection Management, Northwestern University, Evanston, IL, 
`1981‐1989 
`Instructor, Assistant and Associate Professor of Library Administration, University of Illinois at 
`Urbana‐Champaign, Urbana, IL, 1974‐1981 
`
`
`
` 
`During the course of this employment and through graduate study of library science (University of 
`Illinois, M.S., 1976), I have become well informed about the operations of academic libraries. 
`
`This Declaration relates to ITEM 1:  “A randomised, placebo‐controlled phase II trial of a novel oral 
`single‐agent fumarate therapy, BG00012, in patients with relapsing‐remitting multiple sclerosis,” by L. 
`Kappos, D. Miller, R. Gold, E. Havrodova, C. Polman, V. Limmroth, G. O’Neill, and R. Conaghan. 
`
`Initial public availability 
` 
`Item 1 first became available to researchers in a poster session at the 15th Meeting of the European 
`Neurological Society (ENS), in Vienna, on 18‐22 June 2005.  This was one of a series of annual ENS 
`meetings (see http://www.ensinfo.org/congress_past/index.html) that generally attract about three 
`thousand participants from scores of countries and at which a great number of papers and posters are 
`presented.    
` 
`Attachment 1 shows the program prepared for the 2005 meeting, with the notation “Last update 
`10.06.2005.”  Attachment 2 is Item 1 as it appeared in this program, indicating the poster was presented 
`on 22 June 2005.  Attachments 1‐2 derive from the online, fully searchable Web site for the 2005 
`meeting.  This online program was presumably available at least to those attending the meeting no later 
`than 10 June 2005. 
` 
`Item 1 may be understood to have entered the public realm of discourse as early as 10 June 2005 and no 
`later than 22 June 2005. 
` 
`Formal publication 
` 
`Item 1 was formally published in the Journal of Neurology, 22, Supplement 2 (June 2005), p. II/148. This 
`journal is published by Springer for the European Neurological Society, which convened the Vienna 
`meeting. 
`
` 
`
`1 
`
`Page 2 of 13
`
`

`
` 
`Attachment 3 is a copy of the title page of Supplement 2 held at the University of Maryland Health 
`Sciences and Human Services Library, Baltimore, while Attachment 4 is a copy of Item 1 itself.  
`Attachment 5 is a copy of the Supplement Index, showing the entry for Item 1 (P 574) under the first 
`author’s name (L. Kappos). 
` 
`Attachment 3 shows a date stamp indicating this publication was received by the University of Maryland 
`Health Sciences and Human Services Library on 6 July 2005.  Periodical titles, such as the Journal of 
`Neurology, would normally be cataloged by libraries years or decades before a given issue was added to 
`the collection. When individual issues were received by a library, they would be checked in (often with a 
`date stamp), added to library holdings records, and made available for use by readers as soon after their 
`arrival as possible—normally within a few days or (at most) a few weeks.  One may reasonably and 
`conservatively assume the June 2005 Supplement to the Journal of Neurology, where Item 1 was 
`published, was available to readers at the University of Maryland by August 2005. 
` 
`Attachment 6 is a copy of the University of Maryland catalog record for the Journal of Neurology.  
`Attachment 7 is a copy of the OCLC WorldCat record for this title, which shows that the Journal of 
`Neurology is held by almost 600 libraries world‐wide. 
` 
`Even wider access to Item 1 was provided by the Thomson Reuters online indexing service, the Web of 
`Science (see Attachment 8) and by the online SpringerLink entry that provides a PDF download for 
`Poster Session 3, which contains Item 1 (Attachment 9).  There is no direct evidence of when the Web of 
`Science or the SpringerLink online entries for Item 1 became available to researchers.  Both Springer and 
`the Web of Science had a business interest in providing the promptest possible indexing service for 
`material presented at important, widely attended annual meetings of the European Neurological 
`Society.  One may reasonably assume broad online indexing for Item 1 was available by September 
`2005. 
` 
`Summary 
` 
`The available evidence—ENS meeting program and poster session dates, formal publication date, 
`library processing date stamp on the relevant issue of the periodical, and online indexing—
`conclusively indicates that Item 1 entered the realm of public discourse by no later than 22 June 2005 
`and was, through normal publication and indexing channels, available to investigators exercising 
`normal care to understand scholarship relevant to Item 1 by no later than September 2005. 
` 
`In making this Declaration, I have been retained on behalf of Neifeld IP Law, PC.  I understand that this 
`Declaration may be filed by Neifeld IP Law, PC in a contested case before the Patent Trial and Appeal 
`Board of the United States Patent Office, in which Neifeld IP Law, PC is challenging the patentability of 
`patent claims.  I am being paid my company’s standard hourly rate, and no part of my compensation is 
`dependent on the conclusions that I reach or the outcome of the case. 
`
` I
`
` reserve the right to supplement my opinion in the future to respond to any arguments that the Patent 
`Owner raises and to take into account new information as it becomes available. 
`
` I
`
` declare that all statements made herein of my own knowledge are true and that all statements made 
`on information and belief are believed to be true; and further that these statements were made with 
`
` 
`
`2 
`
`Page 3 of 13
`
`

`
`the knowledge that willful false statements and the like so made are punishable by fine or 
`imprisonment, or both, under Section 1001 of Title 18 of the United States Code. 
`
`   
`
`Dated 29 April, 2015. 
`    
`
` 
`
`Scott Bennett 
`Managing Partner 
`Prior Art Documentation Services LLC 
` 
`
`Attachments   
` 
`The following 9 attachments are true and accurate representations of online catalog and bibliographic 
`records, and of library materials.   Attachments 1‐2 and 6‐9 were prepared with Microsoft Snipping Tool 
`software from Internet sites (relevant URLs are provided for each attachment) and incorporated into Word 
`documents for ease of use in this Declaration.  These online records were retrieved on 24‐25 April 2015.  
`Attachments 3‐5 are digital scans made at the University of Maryland Health Sciences and Human Services 
`Library, Baltimore, on 28 April 2005 and transmitted as PDFs.    
` 
`
`Attachment 1: Program cover of the Fifteenth Meeting of the European Neurological Society (ENS) 
`Attachment 2: ENS Meeting Program entry for Item 1 
`Attachment 3: Cover of the Journal of Neurology, 22, Supplement 2 (June 2005) from the University of 
`Maryland 
`Attachment 4: Item 1 from the Journal of Neurology, 22, Supplement 2 (June 2005), p. II/148 
`Attachment 5:  Index entry for Item 1 from the Journal of Neurology, 22, Supplement 2 (June 2005), p. II/164 
`Attachment 6: University of Maryland Library catalog record for the Journal of Neurology 
`Attachment 7: OCLC WorldCat record for the Journal of Neurology 
`Attachment 8: Web of Science entry for Item 1 
`Attachment 9: SpringerLink entry for Item 1 download 
`
`3 
`
` 
`
`  
`
`  
`
` 
`
` 
`
`Page 4 of 13
`
`

`
`Attachment 1: Program cover of the Fifteenth Meeting of the European Neurological Society (ENS) 
` 
`URL: http://www.congrex.ch/2005/ens2005/ 
` 
`
` 
`
` 
`
` 
`
` 
`
`4 
`
`Page 5 of 13
`
`

`
`Attachment 2: ENS Meeting Program entry for Item 1 
` 
`URL: 
`http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=10051&XNSPRACHE_ID=2&XNKONGRESS_ID=
`18&XNMASKEN_ID=900 
` 
`
` 
`
` 
`
` 
`
` 
`
`5 
`
`Page 6 of 13
`
`

`
`urn a
`
`e,uroto
`
`ean
`logical
`
`HS/HSL
`UNIVERSrTY OF MARYlAND
`BAlTIMORE
`
`JUL 6
`
`2005
`
`REC'D.
`
`NOT IN CIRC.
`
`~ ~Springer
`
`line ll
`
`logy I
`
`~~~~ )",>,
`
`.... •
`
`~~·'··· "'~h· ;'~-~~..-.r~~·.,.~~:? ~ 1
`
`... ~·;:::~_;;~_:t:-·J .:-
`
`:-.~o;;~~tf.-~"~::._J§k{o;"·,. ~r.~~~-~ :{:; • ;;r;;·~ '!'
`
`,1<'
`
`,...:·.·~- ~;!:1~.,.·. -.. ": ~~'.;,~I
`
`Page 7 of 13
`
`

`
`creased cortisol serum levels at all five time points as compared toMS pa(cid:173)
`tients in remission. TNFR-1 as well as TNFR-2levels followed a less marked
`(p < 0.05) descending course over the day in all groups. MS patients with
`Gd-enhancement had again significantly (p < 0.05) elevated levels for
`TNFR-1 but not for TNR-2 as compared to healthy donors. In contrast, IL-
`4-R and TNF-beta serum concentrations were relatively stable over the day.
`Both MS groups had significantly (p < 0.05) elevated TNF-beta serum lev(cid:173)
`els at any time point as compared with the control group. Moreover, the
`TNF-beta serum levels were further (p < 0.05) increased in the group with
`active MS patients as compared to patients in remission.
`Conclusion: Our data show that the diurnal rhythmicity of immuno(cid:173)
`logical markers must be considered in at least some of the investigated im(cid:173)
`munological markers. We could not observe a substantial difference in the
`circadian rhythmicity between MS patients and healthy donors. However,
`the increase of cortisol serum levels in MS patients with active disease
`shows that MS disease activity has an at least indirect influence on the cir(cid:173)
`cadian rhythmicity.
`
`randomized to receive BG00012 120mg PO once daily (120mg/day},
`120mg PO three times daily (360mg/day), 240mg PO three times daily
`(720 mg/day), or placebo. The study consists of 2 phases: a 24-week dou(cid:173)
`ble-blind treatment phase followed by a 24-week, blinded, safety-extension
`phase in which all patients will receive some level of BGOOO 12. The primary
`endpoint is the total number of Gd+ lesions over four MRI scans at weeks
`12, 16, 20, and 24 (calculated as the sum of these four MRI scans). Sec(cid:173)
`ondary MRI endpoints include the cumulative number of new Gd+ lesions
`and the number of new or newly enlarging T2-hyperintense lesions at week
`24 compared with baseline. Additional endpoints include: the number of
`new Tl-hypointense lesions at week 24 compared to baseline, safety and
`tolerability, disability progression as measured by EDSS, relapse rate, and
`proportion of relapse-free patients.
`Results: This paper will present details of the study design, as well as
`the baseline demographic and clinical characteristics of enrolled patients.
`Conclusions: This dose-ranging study will determine the efficacy of
`BG00012 on brain lesion activity in patients with RRMS.
`
`P573
`Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2,
`Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients
`M. Ruggieri, C. Avolio, S. Scacco, C. Pica, A. Lia, G. B. Zimatore, S. Papa, P.
`Livrea, M. Trojano
`University of Bari, University of Foggia (Bari, Foggia, I)
`
`P575
`A helper dependent adenovirus efficiently delivers bioactive FGF-II to the
`CNS
`E. Butti, C. Porcheri, A. Bergami, E. Brambilla, A. Cattalini, A. Recchia, A.
`Stornauiolo, F. Mavilio, G. Martino, R. Furlan
`San Raffaele Scientific Institute (Milan, I)
`
`Apoptotic deletion of autoreactive T -cells is defective in patients with Mul(cid:173)
`tiple Sclerosis (MS). Glatiramer Acetate (GA} treatment seems to restore
`apoptosis of detrimental T-cells. We analyzed the mitochondria membrane
`pro- (Bax) and anti-apoptotic (Bcl-2) and cytosolic pro-apoptotic (Cyt-c,
`APAF-1) proteins expression in peripheral lymphocytes from RR MS pa(cid:173)
`tients during GA treatment. Blood samples from 8 RR MS patients, before
`and every three months during 9 months of GA treatment, and from 8
`healthy controls (HCs) were collected. PBMNC Bcl-2,Bax,Cyt-c and APAF-
`1 were quantified by "'-estern blot followed by densitometric scanning and
`Bax/Bcl-2, cytosolic Cyt-c/Bcl-2 and APAF-1/Bcl-2 ratios were calculated.
`The percentage of apoptotic cells was assessed by a dye exclusion test. T(cid:173)
`cells were in vitro tested for oxygen consumption by a respirometric analy(cid:173)
`sis. Bax/Bcl-2, cytosolic Cyt-c/Bcl-2 and APAF-1/Bcl-2 ratios in untreated
`MS patients were significantly (p < 0.05} lower than in HCs. Bax/Bcl-2 ra(cid:173)
`tio increased (p = 0.03) and Cyt-c/Bcl-2 ratio showed a trend to increase
`during 9 months of GA treatment in MS patients. An increase of 85 o/o in the
`rate of apoptotic PBMNCs was observed during treatment. A reduction by
`58 o/o in oxygen consumption by T-cells was evident after GA treatment in
`vitro. Our findings suggest that GA exerts a regulatory effect on peripheral
`T lymphocytes through pro-apoptosis mechanisms involving mitochon(cid:173)
`dria and cytosolic proteins.
`
`P574
`A randomised, placebo-controlled phase II trial of a novel oral single(cid:173)
`agent fumarate therapy, BG00012, in patients with relapsing-remitting
`multiple sclerosis
`L. Kappas, D. Miller, R. Gold, E. Havrdova, C. Polman, V. Limmroth, G.
`O'Neill, R. Conaghan
`University Hospitals Basle, Institute of Neurology, University of Goettin(cid:173)
`gen, General Teaching Hospital Prague, VU Medical Centre, University
`Hospital Essen, Biogen Idee (Basle, CH; London, UK; Goettingen, D;
`Prague, CZ; Amsterdam, NL; Essen, D; Cambridge, USA)
`
`Objective: To determine the efficacy and safety of a novel single-agent oral
`fumarate therapy, BG00012, in patients with relapsing-remitting multiple
`sclerosis (RRMS).
`Background: An open-label pilot study demonstrated that a product
`containing a mixture of fumaric acid esters significantly reduced the num(cid:173)
`ber and volume of gadolinium-enhancing (Gd+) lesions in patients with
`RRMS. BG00012 is being investigated for the treatment of psoriasis and
`other autoimmune diseases, including MS. This phase II study was de(cid:173)
`signed to evaluate the efficacy of three doses of BG00012 on brain lesion
`activity as measured by magnetic resonance imaging (MRI) in patients
`withRRMS.
`Design: This is a randomized, double-blind, placebo-controlled, phase
`II study being conducted at 45 clinical centers in Europe. Patients were in(cid:173)
`cluded in the study if they were between 18 and 55 years of age, had a def(cid:173)
`inite diagnosis of RRMS, and an Expanded Disability Status Scale (EDSS)
`score between 0.0 and 5.0. In addition, patients must have either experi(cid:173)
`enced at least 1 relapse within 12 months prior to randomization with le(cid:173)
`sions on cranial MRI consistent with MS, or had Gd+ lesions on a cranial
`MRI performed within 6 weeks of randomization. Eligible patients were
`
`We tested a FGF-11-expressing HD-Ad vector called STK120-GFP-FGFII in
`naive mice focusing on the ability of FGF-ll to induce stem cells prolifera(cid:173)
`tion and migration. We injected naive C57BL/6 mice in the cisterna magna
`with 10"8 transducing unit (t. u.) of STK120-GFP-FGFII; control mice re(cid:173)
`ceived the"empty" STK!20-GFP vector. Mice were sacrificed at 7,14,21 and
`28 days post injection. We administered BrdU to the mice to mark all pro·
`liferating cells. Preliminary analysis showed ventricular enlargement in
`STK120-GFP-FGF-II-injected mice; this was evident one week post injec(cid:173)
`tion and persisted 4 weeks thereafter. We then performed BrdU staining by
`immunochemistry and counted BrdU positive cells near the lateral ventri(cid:173)
`cles. STK120-GFP-FGFII-injected mice displayed a three-fold increase in
`BrdU positive cells as compared to control mice. This increase was already
`present one week after the treatment, and persisted at 2 and 3 weeks after
`injection, but disappeared 4 weeks after vector administration.
`
`P576
`Immunoablation using cyclophosphamide without haematopoietic stem
`cell rescue for refractory multiple sclerosis
`M. Ko, G. Katsamakis, D. Stefoski, f. Shammo, S. Gregory
`Rush University Medical Center (Chicago, USA)
`
`Objective: To assess safety and efficacy of very high dose cyclophos·
`phamide (CYP) without hematopoietic stem cell (HSC) rescue for in(cid:173)
`tractable multiple sclerosis (MS), as a realistic substitute for autologous
`HSC transplantation.
`Background: Immunoablation without HSC rescue has been beneficial
`in other autoimmune diseases (eg, C!DP, SLE, myasthenia gravis) and may
`thus be a viable therapeutic option for intractable MS. No such data have
`been published. The aldehyde dehydrogenase mediated resistance of HSCs
`to CYP allows for reconstitution of a potentially advantageous naive im·
`mune system.
`Study Design: We initiated an IRE-approved study of ten patients with
`intractable MS, defined as having recurring relapses, worsening clinical
`deficits, and frequent contrast-enhancing lesions on MRI over 6 to 12
`months in spite of conventional therapies with immunomodulators and
`immune suppressants. Patients will receive immunoablative doses of CYP
`200 mg/kg divided over 4 days, similar to previously published studies. On
`day 10, patients will start granulocyte-colony stimulating factor ( G-CSF,
`51-!g/kg/day), until the absolute neutrophil count (ANC) rises to 0.5 x
`10"9/L for 2 days. Following immunoablation, clinical, EDSS, laboratory
`and MRI follow-ups will occur at three to six month intervals over one year.
`Case Report: A 23-year-old woman with relapsing MS for 3 years pre(cid:173)
`sented with ataxia, cognitive and behavior decline, and increasing burden
`of gadolinium enhancing lesions on serial brain MR!s. She had failed in(cid:173)
`terferon-beta, glucocorticoids, and three courses of tv CYP (1000 mg/m2).
`Immunoablation resulted in leukopenia (WBC trough of 44 x 106/L by day
`11), and was> 0.5 x 109/L by day 15 (day 6 of G-CSF). No new neurologic
`symptoms or signs developed during and after the treatment period. We
`will show detailed longitudinal clinical, MRI, and laboratory metrics from
`this first in the series of our study subjects.
`Conclusion: To our knowledge, this is the first published report of im·
`munoablation in recalcitrant MS using high dose CYP without HSC rescue.
`
`It appe(cid:173)
`tive to
`
`P577
`Magne
`trolled
`E.-W.F
`F. Lubl
`for the:
`
`Object
`terferc
`formal
`sis (M:
`Ba·
`mator(cid:173)
`(MRI)
`with 1:
`Natali~
`brain
`perim
`dition
`patien
`Sh.
`trollec
`receiv(cid:173)
`izatiol
`ous 1~
`orpla.
`dard 1
`for up:
`newo(cid:173)
`enhar.:
`Re
`data a~
`Thea.
`or enl
`them.
`with I
`natali
`treate
`the a,
`of pal
`and 11
`
`IFN~ c.
`
`activi
`IFN~
`IFN~
`
`P578
`The •
`multi
`W.S<
`Lubli
`forti-
`
`Obje·
`adde(cid:173)
`grou:
`B;
`ofna
`53o/o
`nanc
`hanc
`anal•
`thee
`less;
`s;
`troll·
`ceive
`weeb
`larlr
`the 1
`laps•
`grou
`2,>:
`
`Page 8 of 13
`
`

`
`11/164
`
`Huh,K . . . . . . . . . . . . . . . . . . . . Pl90
`Hurwitz, B.J.
`. . . . . . . . . . . . . . . . P485
`Hurwitz, S . . . • . . . . . . . . . . . . . . . 047
`Husson, H.
`. . . . . . . . . . . . . . . . . P612
`Hutchinson, M.
`. .. 0104,0157,0159,
`0160,P492,P560,P579
`
`. . . . . . . . . . . . . . . . . P437
`Iannetti, G.
`Iannucci, G. . . . . . . . . . . . . . . . . . P208
`Ibrahim, F. . . . . . . . . . . . . . . P216, P595
`Ibrahim, M. . .
`P269
`Ibrahim, S.M.
`P315
`Iconomou, G. .
`P428
`!done, D.
`P371
`Ike,A. . . . . .
`P238
`Has, J, . . . . .
`P308
`Ilhan, A. . . . .
`P545
`.
`Ilsbroukx, S.
`. P343
`Iltumur, K . . . . . . . . . . . . . . . P443, P444
`!nee, P. G . . . . . . . . . . . . . . . . . . . . 057
`Infante, J.
`. . . . . . . 0101,0142,0150, P481
`Inglese, M.
`. . . . . . . . . . . . . . . . . P207
`Iniguez Martinez, C . . . . . . . . . . . . . P402
`Inoue, K . . . . . . . . . . . . . . . . 0126, P184
`Inshashi, J, . . . . . . . . . . . . . . . . . P276
`. . . . . . . . . . . . . . . . . . P611
`Insola, A.
`Inuggi, A.
`. . . . . . . . . . . . . . . . . . 030
`Joannidis, P.
`. . . . . . . . . . . . . P408, P484
`Iranzo, P . . . . . . . . . . . . . . . . . . . . 029
`lrie, T. . . . . . . .
`P591
`Irlbacher, K.
`. . . . . . . . . . . . . . . . P430
`Isnard-grivaux, F.
`. . . . . . . . . . . . . P524
`. . . . . . . . . . . . . . P224, P224
`Iuliano, G.
`Izworski,A. . .
`.. P373
`"'
`
`. . . . . . . . . . . . . . . . . . P412
`Jacobi, C.
`Jacquemyn, Y. . . . . . . . . . . . . . . . . P384
`Jahn, K . . . . . . . . . . . . . . . . . P259, P592
`Jakeman, P.
`. . . . . . . . . . P226, P330, P332
`Jakobs, P.
`. . .
`P485
`Jang, B. C. . . .
`P584
`Janghorban, P.
`P209
`Jangouk, P.
`.
`P341
`Jann, S.
`. . . .
`P516
`Janowska, J. . .
`Pl87
`Jans, P . . . . . . . . . . . . . . . . . . . . . 018
`Jansen, 0 . . . . . . . . . . . . . . . . . . . Pl82
`Jaraquemada, D.
`. . . . . . . . . . . . . . P426
`Jarius, S . . . . . . . . . . . . . . . . 0114,0171
`Jasinska-Myga, B.
`. . . . . . . . . . . . . P465
`Jeffery, D. R. . . . . . . . . . . . . . . . . . P485
`]ellinger, K.. . . . . . . . . . . . . . . . . 0117
`Jenkinson, P.M.
`. . . . . . . . . . . P238, P501
`Jeong, H. W . . . . . . . . . . . P280, P281, P449
`Jerabek, J . . . . . . . . . . . . . . . . . . . P599
`Jishi, A.
`. . . . . . . . . . . . . . . . . . . P276
`Jones, P. W . . . . . . . . . . . . P238, P270, P501
`Jones, S. J.
`. . . . . . . . . . . . . . 0113, P490
`Joo, I. . . .
`Pl90
`Joodi, Z. . .
`P600
`Jox,R.. . .
`P406
`Jumma, M.
`P276
`Jung, D. S. .
`P446
`Jung, J. B . . . . . . . . . . . . . . . . P263, P282
`P327
`Jung, Y. M. .
`]iittler, E.
`.
`P412
`
`P485
`Kaba, S. . .
`Kaeufer, T.
`P316
`P338
`.
`Kaimen-Maciel, D. R.
`P285
`Kajikawa, H.
`. . . . . .
`Kalaboki, E.
`. . . . . . . . . . . . . P307, P510
`Kale, S. S . . . . . . . . . . . . . . . . . . . . 044
`Kalofonos, H. . .
`. P428
`Kalski, G. . . . . . . . . . . . . . . . . .. P503
`Kamal, Y. S . . . . . . . . . . . . . . . . . . PS29
`Kambouris,M . . . . . . . . . . . . . . . . 0119
`Kampman, M. T.
`. . . . . . . . . . . . . . P411
`Kamran, S . . . . . P216, P276, P277, P440, P595
`Kanda, F. . . . . . . . . . . . . . . . . . . P591
`
`Kandinov, B. . . . . . . . . . . . . . . . . . 098
`Kandyla, B. . .
`P268
`Kang, S. ]. . . .
`. P405
`Kanovsky, P.
`.
`. P369
`Kapczynski, P.
`. P203
`. .
`Kapeller, P.
`. P339
`Kapinos, M. . .
`. P203
`Kappelle, L. J, .
`. P359
`. 035,0136,0141,0158,
`Kappos, L.
`0159,0160, P487, P492,
`P504,P574,P579
`Kaps, M . . . . . . . . . . . . . . . . . 091, P570
`Karakaya, 0.
`.
`P336
`Karandreas, N . . . . . . . . . . . . . . . . P519
`Karantanas,A . . . . . . . . . . . . . . . . P314
`. . . . . . . . . . . . . . . . . Oll8
`Karelis, G.
`Kariv lnbal, Z.
`. . . . . . . . . . . . . . . P241
`Karlsson, T.
`. . . . . . . . . . . . . . . . . 028
`Karni,A.- . . . . . . . . . . . . . . . . . . P571
`. . . . . . . . . . . . . . . . . P340
`Karouli, M.
`Karussis, D . . . . . . . . . . . . . . . . . . 0!52
`Karwacka, M . . . . . . . . . . . . . . . . . P618
`Kaseda, Y. . . . . . . . . . . . . . . . . . . P285
`Kaskel, P.
`. . . . . . . . . . . 0136, P234, P499
`Kastenbauer, S. . . . . . . . . . . . . . . . 0116
`Katsamakis, G. . . . . . . . . . . . . . . . P576
`Katz,M . . . . . . . . . . . . . . . . . . . . 099
`Kawarai, T . . . . . . . . . . . . . . . . . . 0129
`Kay, C. S. K . . . . . . . . P328, P432, P433, P506,
`P515,P609
`Kaya, N. . . . . . .
`P444
`P365
`Kazibutowska, Z. .
`P214
`Kefi,M. . . . . . .
`P283
`Keir, G.
`. . . . . .
`Kelso, A. R. C.
`. . . . . . . . . . . . . . . . 048
`Kennett, R . . . . . . . . . . . . . . . . . . 0161
`Kerckhofs, E. . . . . . . . . . . . . . . . . P343
`Khajavi, M . . . . . . . . . . . . . . . . . . 0126
`KhalilAzar,H . . . . . . . . . . . . . . . . P517
`Khan, 0 . . . . . . . . . . . . . . . . 0137, P489
`Khoja, W. . . . . . . . . . . . . . . . . . . P276
`Khorvash, F.
`. . . . . . . . . . • . . . . . P614
`Khurana, D . . . . . . . . . . . . . . . . . . P355
`Kiefer, R . . . . . . . . . . . . . . . . . . . . 073
`Kilic, E . . . . . . . . . . . . . . . . . P290, P368
`Kilic, U . . . . . . . . . . . . . . . . . P290, P368
`Kilidireas, C.
`. . . . . . . P519
`Kim, D. W . . . . . . . . . . . . . . . . . . . P445
`Kim, D. H. . . . . . . . . . . . . . . . . . . P449
`Kim, E. J, . . . . . . . . . . . . P289, P401, P405
`Kim, G. H . . . . . . . . . . . . . . . . . . . P584
`Kim, H. J . . . . . . P247, P280, P281, P327, P449
`P282
`Kim, H. S. .
`Kim, H. T. .
`. . . . P459
`Kim, H. Y . . . . . . . . . . . . . . . . . . . P616
`Kim, J. I. ................... P381
`Kim, J. S . . . . . . . . . . . . . . . . P460, P461
`Kim, J. Y.
`. . . . . . . . . . . . . . . . . . P588
`Kim, K. S.
`. . . . . . . . . . . . . . . . . . 073
`Kim,M...
`P327
`Kim, S. H. .
`P198
`Kim, S. W..
`P198
`Kim, W. J, .
`P460
`Kim, Y. I.
`P202
`.
`Kim, Y. J . . . . . . . . . . . . . . . . P288, P451
`Kimova, M. V. . . . . . . . . . . . . . . . . P345
`Kirby,].
`. . . . . . . . . . . . . . . . . . . 057
`Kirchhoff, I. . . . . . . . . . . . . . . . . . 033
`Kirzinger, S. S.
`. . . . . . . . . . . . . . . P485
`Kis,B . . . . . . . . . . . . . . . . . . . . . 018
`Kitchen,N . . . . . . . . . . . . . . . 017,P283
`Kivity, S.
`. . .
`Pl93
`Kkolou, E. . . . . . . . . . . . . . . . . . . P298
`Klapczynski, F. . . . . . . . . . . . . . . . P476
`Klein, C. . . . . . . . . . . . . . . . . . . . 097
`Kleinschnitz, C. . . . . . . . . . . . . . . . 025
`Kleiser, R. . . . . .
`. P389
`Klinghammer, 0. . . . . . . . . . . . . . . P225
`Klinker, E. . . . . . . . . . . . . . . . . . . P497
`Klockgether, T.
`. . . . . . . . . . . . . . . 036
`
`Klopstock, T. . . . . . . . . . . . . . . . . 0124
`Knezevic, Z. . . . . . . . . . . . . . . . . . PS42
`Knipp, S.
`. . . . . . . . . . . . . . . . . . 0138
`Ko,M . . . . . . . . . . . . . . . . . . . . . P576
`Kobayashi, A. . . . . . . . . . . . . . . . . P450
`Kocer,A . . . . . . . . . P197, P336, P434, P473,
`P520,P545
`. . . . . . . . . . . . . . . . . P315
`Koczan, D.
`Kodounis, A.
`. . . . . . . . . . . . . . . . P360
`Kodras, K.
`. . . . . . . . . . . . . . P266, P309
`Koedel, U . . . . . . . . . . . . . . . . . . . 0116
`Koenig, N.
`. . . . . . . . . . . . . . . . . P422
`Kohler, W. . . . . . . . . . . . . . . . . . . P385
`Kolotvinov, V.
`. . . . . . . . . . . . . . . . 027
`Komnos, A . . . . . . . . . . . . . . . . . . P314
`Kompf, D . . . . . . . . . . . . . . . . . . . 0108
`Konczak, J. . . . . . . . . . . . . . . . . . 0103
`Kondakova, 0.
`. .. P179
`Konig, H.
`. . .
`. . . P494
`Konitsiotis, S. .
`. .. P457
`Kontaxis, T. . .
`. . . P317
`Koo, B. D. . . .
`. . . P289
`Kopp, U . . . . . . . . . . . . . . . . . . . . 056
`. . . . . . . . . . . . . . 098, P193
`Korczyn, A.
`Korn,A . . . . . . . . . . . . . . . . . . . . 0141
`Kornek, B . . . . . . . . . . . . . . . . . . . PS02
`Koronkiewicz, M.
`. . . . . . . . . . . . . P411
`Korporal, M . . . . . . . . . . . . . . . 063,072
`Kos,D.. . . . . . . . .
`. ... P343
`Kosmidis, M. . . . . . . . . . . . . . . . . P484
`Kosocki-Rakonic, S . . . . . . . . . . . . . PS46
`Kotowicz, J.
`. . . . . . . . . . . . . . . . . 092
`Kotzki, P.
`. . . . . . . . . . . . . . . . . . P370
`Kouremenos, E.
`. . . . . . . . . . . P246, P360
`Koutoula, 0 . . . . . . . . . . . . . . P194, P610
`Koutras, A.
`. . . . . . . . . . . . . . . . . P418
`Koutsis, G.
`. . . . . . . . . . . . . . . . . P317
`Koutsouraki, E.
`. . . . . . . . . . . P295, P472
`Kozlowski, 0.
`. . . . . . . . . . . . 0143, P261
`Kramer, H. H. . . . . . . . . . . . . . . . . P223
`Kramer, P . . . . . . . . . . . . . . . . . . . Pl91
`Krammer, P. . • . . . . . • . . . . . • . . . 063
`Krarup, C.
`. . . . . . . . . . . . . . . . . 0169
`Kraus, J . . . . . . . . . . . . . . 073, P570, P572
`Krause, P. .
`. . . P585
`Krauss, J.
`.
`... P316
`Krauss, M.
`. . . P225
`Krcova, V. .
`. . . P358
`Kreiling, A.
`. . . PS72
`Kretzschmar, H.
`. . . P259
`Krishnan, K. J, . . . . . . . . . . . . . . . 0124
`Krivoshapkin, A. L. . .
`. . . PS97
`Krivoshey, D.
`. . . P260
`Krstacic, A. . . . . . . . . . . . . . . . . . P361
`Krstacic, G . . . . . . . . . . . . . . . . . . P361
`Krueger, S. . . • . . . . . • . . . . . . . . . 039
`Krumina,A.
`. . . . . . . . . . . . . . . . 0118
`.
`Krupka, B.
`. . . P358
`Ku, B. D. . . .
`. .. P401
`Kuck, K . . . . . . . . . . . . . . . . . . . . Pl92
`Kuhne, B.s . . . . . . . . . . . . . . . . . . P570
`Kuhne, D.
`. . . . . . . . . . . . . . . . . . 018
`Kuhnert, A. . . . . . .
`. . . . . . . . . P502
`Kuhtz-Buschbeck, J.
`. . . . . . . . . . . . Pl82
`Kumar, C. . . . . . . . . . . . . . . . . . . P212
`Kumru, H.
`. . . . . . . . . . . . . . PSS3, P602
`Kurowska, K. . .
`. .. P411
`Kushnir, M. . . . . . . . . . . . . . . . . . P555
`Kutlar, M. . . . . . . . . . . . . . . . . . . Pl97
`Kutzelnigg,A . . . . . . . . . . . . . 0131,0132
`. .. P396
`Kwon, J, B. . .
`Kwon, K.-H..
`. . P419
`Kwon, 0. S.
`.
`. . P400
`Kwon, 0. Y.
`.
`. . P445
`Kyriazis, H. .
`. . P320
`
`. .. P370
`. .
`Labauge, P.
`. . . . . . . . . . P203, P525
`Labuz-Roszak, B.
`. .. P326
`Lacerda, G.
`. .
`Lachapelle, F. . . . . . . . . . . . . . . . . P491
`
`Page 9 of 13
`
`

`
`Attachment 6: University of Maryland Library catalog record for the Journal of Neurology 
` 
`URL: http://umaryland.worldcat.org/title/journal‐of‐neurology/oclc/43302331&referer=brief_results 
`
`  
`
` 
`
` 
`
` 
`
` 
`
`7 
`
`Page 10 of 13
`
`

`
`Attachment 7: OCLC WorldCat record for the Journal of Neurology 
` 
`URL: 
`http://firstsearch.oclc.org/WebZ/FSQUERY?dbname=WorldCat:searchtype=idblink:format=BI:next=html
`/records.html:bad=html/records.html:numrecs=10:index1=no%3A:term1=43302331:sessionid=fsapp4‐
`43461‐i8vy9um1‐hj0w06:searchtype=advanced 
`
`  
`
` 
`
` 
`
` 
`
` 
`
`8 
`
`Page 11 of 13
`
`

`
`Attachment 8: Web of Science entry for Item 1 
` 
`URL: 
`http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=1
`&SID=3DcAUKvA7dYYh3Bav2G&page=1&doc=1 
`
`  
`
` 
`
` 
`
`9 
`
`   
`
` 
`
`Page 12 of 13
`
`

`
`Attachment 9: SpringerLink entry for Item 1 download 
` 
`URL: http://link.springer.com/journal/415/252/2/suppl/page/1 
`
`  
`
` 
`
`10 
`
`   
`
` 
`
`    
`
` 
`
`Page 13 of 13